PureTech Health PLC (PRTC) is a Healthcare · Biotechnology company listed on NASDAQ. Price $16.50 (-3.11%), Market cap $0.42B, 52-week low–high $14.50 ~ $19.84.
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patients with psychiatric and neurological conditions. In addition, the company develops hydrogels to enable the oral administration of peptide therapeutics
Financial statements, price targets, institutional (13F) holdings and related news for PureTech Health PLC are updated in real time on BlackAll Trade.
PureTech Health PLC trades at $16.50 (-3.11%). Real-time quotes and charts are available on BlackAll Trade.
PureTech Health PLC has a market cap of about $0.42B.
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to tre